Terbutaline appears to have survived the threat of losing its PBS subsidy, although funding for the inhaled therapy is likely to be restricted.

PBS scripts for the short-acting beta-2 agonist, which is delivered via a dry powder inhaler, have been declining for the past four years to about 90,000 in 2018.